Delveinsight

FEBRUARY 25, 2021

Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

DECEMBER 14, 2023

We find that scientists in early-stage drug discovery are very creative, very innovative and extremely helpful. But it comes with surface charge that will absorb proteins, DNA, and other things, unless you do something to treat that surface. Most importantly, we learned that a microplate should be an invisible carrier of an assay.

Drugs 52

Drugs Production Protein Genetic Analysis 52

Drug Discovery World

FEBRUARY 28, 2023

As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta , PhD, staff scientist in genetic sciences at Thermo Fisher Scientific.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52